| Ident. | Authors (with country if any) | Title |
|---|
| 000006 (2015) |
Mark Hallett [États-Unis] ; Jose Obeso | Where does chorea come from? cortical excitability findings challenge classic pathophysiological concepts. |
| 000011 (2015) |
Roberto Erro [Italie] | VPS35 and EIF4G1 interactions and novel candidate genes for PD: from genes to pathways and back. |
| 000014 (2015) |
S. Thobois [France] | USP30: a new promising target for Parkinson's disease? |
| 000039 (2015) |
Stanley Fahn [États-Unis] | The medical treatment of Parkinson disease from James Parkinson to George Cotzias. |
| 000105 (2015) |
Christina M. Lill [Allemagne] ; Lars Bertram | Probing the epigenome by EWAS: a new era in brain disease research. |
| 000109 (2015) |
Eugene V. Mosharov [États-Unis] ; Anders Borgkvist ; David Sulzer | Presynaptic effects of levodopa and their possible role in dyskinesia. |
| 000128 (2015) |
Marjan Jahanshahi [Royaume-Uni] ; Ignacio Obeso ; Christelle Baunez ; Manuel Alegre ; Paul Krack | Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity. |
| 000139 (2015) |
Werner Poewe [Autriche] ; Angelo Antonini | Novel formulations and modes of delivery of levodopa. |
| 000157 (2015) |
José Fidel Baizabal-Carvallo [États-Unis] ; Francisco Cardoso ; Joseph Jankovic [États-Unis] | Myorhythmia: phenomenology, etiology, and treatment. |
| 000176 (2015) |
Michael Samuel [Royaume-Uni] ; Maria Rodriguez-Oroz ; Angelo Antonini ; Jonathan M. Brotchie ; Kallol Ray Chaudhuri ; Richard G. Brown ; Wendy R. Galpern ; Melissa J. Nirenberg ; Michael S. Okun ; Anthony E. Lang | Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. |
| 000190 (2015) |
T Celeste Napier [États-Unis] ; Jean-Christophe Corvol ; Anthony A. Grace ; Jamie D. Roitman ; James Rowe ; Valerie Voon ; Antonio P. Strafella | Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. |
| 000192 (2015) |
C Warren Olanow [États-Unis] | Levodopa: effect on cell death and the natural history of Parkinson's disease. |
| 000203 (2015) |
Stella M. Papa [États-Unis] ; Thomas Wichmann [États-Unis] | Interaction between hyperdirect and indirect basal ganglia pathways. |
| 000213 (2015) |
Oscar S. Gershanik [Argentine] | Improving L-dopa therapy: the development of enzyme inhibitors. |
| 000250 (2015) |
Ji Hyun Ko [États-Unis] ; Renata P. Lerner ; David Eidelberg | Effects of levodopa on regional cerebral metabolism and blood flow. |
| 000286 (2015) |
Nathan C. Rowland [États-Unis] ; Philip A. Starr ; Paul S. Larson ; Jill L. Ostrem ; William J. Marks ; Daniel A. Lim | Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease. |
| 000294 (2015) |
Camila Catherine Aquino [Canada] ; Susan H. Fox | Clinical spectrum of levodopa-induced complications. |
| 000295 (2015) |
Daniel Weintraub [États-Unis] ; Anthony S. David ; Andrew H. Evans ; Jon E. Grant ; Mark Stacy | Clinical spectrum of impulse control disorders in Parkinson's disease. |
| 000309 (2015) |
Isabelle Beaulieu-Boire [Canada] ; Anthony E. Lang | Behavioral effects of levodopa. |
| 000316 (2015) |
Mohamed Jaber [France] | Autism is (also) a movement disorder. |
| 000326 (2015) |
Christos Ganos [Allemagne] ; Andreas Hartmann | Altered cholinergic neurotransmission in Tourette syndrome. |
| 000357 (2014) |
Alexander Lehn [Royaume-Uni] | Will next-generation sequencing also take us to the next level of understanding disease mechanisms? |
| 000359 (2014) |
Brit Mollenhauer [Allemagne] ; Lynn Rochester [Royaume-Uni] ; Alice Chen-Plotkin [États-Unis] ; David Brooks [Royaume-Uni, Danemark] | What Can Biomarkers Tell Us About Cognition in Parkinson's Disease? |
| 000361 (2014) |
Carole Hyacinthe [France] ; Imad Ghorayeb | Wake up with a new brain! |
| 000368 (2014) |
Javier Blesa [États-Unis] | VMAT2 and Parkinson's disease: old dog, new tricks. |
| 000369 (2014) |
Souha Mahmoudi [Canada] ; Daniel Lévesque ; Pierre J. Blanchet | Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. |
| 000379 (2014) |
Connie Marras [Canada] ; Alexander I. Tröster ; Jaime Kulisevsky ; Glenn T. Stebbins | The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease. |
| 000381 (2014) |
Jennifer G. Goldman [États-Unis] ; Caroline Williams-Gray [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; John E. Duda [États-Unis] ; James E. Galvin [États-Unis] | The spectrum of cognitive impairment in Lewy body diseases |
| 000384 (2014) |
Jeffrey H. Kordower [États-Unis] | The prion hypothesis of Parkinson's disease: this hot topic just got hotter. |
| 000388 (2014) |
Anna Castrioto [France] ; Céline Piscicelli ; Dominic Pérennou ; Paul Krack ; Bettina Debû | The pathogenesis of Pisa syndrome in Parkinson's disease. |
| 000390 (2014) |
Erwan Bezard [République populaire de Chine] ; Elsa Y. Pioli ; Qin Li ; Françoise Girard ; Vincent Mutel ; Charlotte Keywood ; Francois Tison ; Olivier Rascol ; Sonia M. Poli | The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. |
| 000393 (2014) |
Marina Papoutsi [Royaume-Uni] ; Izelle Labuschagne ; Sarah J. Tabrizi ; Julie C. Stout | The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation. |
| 000398 (2014) |
Glenda M. Halliday [Australie] ; James B. Leverenz [États-Unis] ; Jay S. Schneider [États-Unis] ; Charles H. Adler [États-Unis] | The Neurobiological Basis of Cognitive Impairment in Parkinson'S Disease |
| 000404 (2014) |
Andrew B. West | Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic |
| 000406 (2014) |
Edward J. Wild ; Sarah J. Tabrizi | Targets for future clinical trials in Huntington's disease: What's in the pipeline? |
| 000407 (2014) |
Barbara Picconi [Italie] ; Paolo Calabresi | Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease? |
| 000408 (2014) |
J Mark Cooper [Royaume-Uni] ; Pb Oscar Wiklander [Suède] ; Joel Z. Nordin [Suède] ; Raya Al-Shawi [Royaume-Uni] ; Matthew J. Wood [Royaume-Uni] ; Mansi Vithlani [Royaume-Uni] ; Anthony H V. Schapira [Royaume-Uni] ; J Paul Simons [Royaume-Uni] ; Samir El-Andaloussi [Suède, Royaume-Uni] ; Lydia Alvarez-Erviti [Royaume-Uni] | Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice |
| 000416 (2014) |
Philip Seibler [Allemagne] ; Christine Klein | Stimulus-triggered acquisition of pluripotency: revolutionizing human disease modeling and regenerative therapies? |
| 000417 (2014) |
Anne Rosser [Royaume-Uni] ; Clive N. Svendsen | Stem cells for cell replacement therapy: a therapeutic strategy for HD? |
| 000422 (2014) |
David G. Standaert ; C Warren Olanow ; José A. Obeso | Scientific perspectives. |
| 000427 (2014) |
Sheila M. Fleming [États-Unis] ; Alberto J. Espay | Ribosomal s15: A novel therapeutic target for Parkinson's disease. |
| 000429 (2014) |
Jay S. Schneider [États-Unis] ; Mark E. Ault ; David W. Anderson | Retinal pathology detected by optical coherence tomography in an animal model of Parkinson's disease. |
| 000449 (2014) |
Talene A. Yacoubian [États-Unis] ; David G. Standaert | Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration. |
| 000455 (2014) |
Nobutaka Hattori [Japon] | REST as a new therapeutic target for neurodegenerative disorders. |
| 000456 (2014) |
Allan Mccarthy [Irlande (pays)] ; John Mckinley ; Tim Lynch | Putting the downstream breaks on neurodegeneration? |
| 000459 (2014) |
Abhishek Chandra ; Ashu Johri ; M. Flint Beal | Prospects for Neuroprotective Therapies in Prodromal Huntington's disease |
| 000468 (2014) |
Raul Martinez-Fernandez [France] ; Anna Castrioto ; Paul Krack | Prefrontal--STN projections, the highway for emotion and cognition control. |
| 000472 (2014) |
Thomas Philips [États-Unis] ; Jeffrey D. Rothstein ; Mahmoud A. Pouladi | Preclinical models: needed in translation? A Pro/Con debate. |
| 000473 (2014) |
Mathieu Favier [France] ; Theo Duran ; Carole Carcenac ; Guillaume Drui ; Marc Savasta ; Sebastien Carnicella | Pramipexole reverses Parkinson's disease-related motivational deficits in rats. |
| 000480 (2014) |
C Warren Olanow [États-Unis] ; Dustin R. Wakeman ; Jeffrey H. Kordower | Peripheral alpha-synuclein and Parkinson's disease. |
| 000486 (2014) |
Darius Ebrahimi-Fakhari [États-Unis] ; Lara Wahlster ; Mustafa Sahin | Parkinson's disease: A disorder of axonal mitophagy? |
